OncoSec Medical Inc (ONCS) CEO Acquires $25,000.50 in Stock

OncoSec Medical Inc (NASDAQ:ONCS) CEO Daniel J. O’connor bought 16,667 shares of OncoSec Medical stock in a transaction that occurred on Monday, February 5th. The shares were acquired at an average price of $1.50 per share, for a total transaction of $25,000.50. Following the acquisition, the chief executive officer now directly owns 16,667 shares in the company, valued at approximately $25,000.50. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

Shares of OncoSec Medical Inc (ONCS) traded down $0.09 during mid-day trading on Tuesday, reaching $1.67. 367,613 shares of the company’s stock were exchanged, compared to its average volume of 1,026,644. OncoSec Medical Inc has a 52-week low of $0.88 and a 52-week high of $2.95. The firm has a market cap of $61.80, a price-to-earnings ratio of -1.69 and a beta of 3.37.

Several research firms recently weighed in on ONCS. HC Wainwright set a $6.00 target price on shares of OncoSec Medical and gave the company a “buy” rating in a report on Friday, January 19th. Maxim Group set a $5.00 target price on shares of OncoSec Medical and gave the company a “buy” rating in a report on Thursday, December 14th. Finally, ValuEngine lowered shares of OncoSec Medical from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. OncoSec Medical presently has an average rating of “Buy” and a consensus target price of $5.33.

WARNING: This piece was posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/06/oncosec-medical-inc-oncs-ceo-acquires-25000-50-in-stock.html.

OncoSec Medical Company Profile

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.

Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply